Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979830 | 0.90 | ALDH1A1 (0.50) | SYKKDRALDH1A1MAPKAPK2TERT | |
| SCHEMBL15466083 | 0.83 | DOT1L (0.43) | ALDH1A1ROCK2TERTDOT1L | |
| SCHEMBL879559 | 0.80 | ROCK2 (0.52) | SYKKDRALDH1A1MAPKAPK2ROCK2 | |
| SCHEMBL3459248 | 0.78 | IGF1R (0.46) | SYKKDRMAPKAPK2ROCK2AURKA | |
| SCHEMBL2598750 | 0.78 | MEN1 (0.43) | KDRMAPKAPK2TERTDOT1L | |
| SCHEMBL12612817 | 0.77 | ROCK2 (0.55) | SYKKDRMAPKAPK2ROCK2AURKA | |
| SCHEMBL13485393 | 0.76 | KDM4E (0.44) | KDRALDH1A1TERTDOT1LHTR3E | |
| SCHEMBL6312915 | 0.76 | IGF1R (0.52) | SYKKDRALDH1A1MAPKAPK2AURKA | |
| SCHEMBL20611795 | 0.75 | MAPKAPK2 (0.50) | KDRMAPKAPK2 | |
| SCHEMBL12776139 | 0.75 | KDR (0.60) | SYKKDRMAPKAPK2TERTDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688883-B1 | PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2016-05-18 | — | — | EP | disclosed |
| EP-2688883-B1 | PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2016-05-18 | — | — | EP | disclosed |
| EP-2571867-B1 | NOVEL PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| EP-2571867-B1 | NOVEL PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| US-9006241-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-04-14 | — | — | US | disclosed |
| US-9006241-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-04-14 | — | — | US | disclosed |
| US-8927547-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-01-06 | — | — | US | disclosed |
| US-8927547-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-01-06 | — | — | US | disclosed |
| US-20140045845-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045845-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2014-02-13 | — | — | US | disclosed |
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2013-04-11 | — | — | US | disclosed |
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2013-04-11 | — | — | US | disclosed |
| EP-2502924-A1 | Novel pyrimidine derivatives | Chemilia AB (SE) | 2012-09-26 | — | — | EP | disclosed |
| EP-0862560-B1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-6235746-B1 | AUTOIMMUNE DISEASES; ANTIPROLIFERATIVE AGENT | CELLTECH THERAPEUTICS, LIMITED (GB) | 2001-05-22 | — | — | US | disclosed |
| US-5958935-A | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-09-28 | — | — | US | disclosed |
| EP-0862560-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997019065-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045845-A1 | NOVEL PYRIMIDINE DERIVATIVES | TYMS, DPYD, TYMP | SYK 2886/4885KDR 2073/4885ALDH1A1 419/4885 |
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | SYK 3374/4885KDR 1568/4885ALDH1A1 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.